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We previously demonstrated in streptozotocin-induced diabetic mice that deﬁciency or inhibition of aldose reductase (AR) caused
signiﬁcantdephosphorylationofhepatictranscriptionalfactorPPARα,leadingtoitsactivationandsigniﬁcantreductionsinserum
lipid levels. Herein, we report that inhibition of AR by zopolrestat or by a short-hairpin RNA (shRNA) against AR caused a
signiﬁcant reduction in serum and hepatic triglycerides levels in 10-week old diabetic db/db mice. Meanwhile, hyperglycemia-
induced phosphorylation of hepatic ERK1/2 and PPARα was signiﬁcantly attenuated in db/db mice treated with zopolrestat or AR
shRNA. Further, in comparison with the untreated db/db mice, the hepatic mRNA expression of Aco and ApoA5, two target genes
for PPARα, was increased by 93% (P<0.05) and 73% (P<0.05) in zopolrestat-treated mice, respectively. Together, these data
indicate that inhibition of AR might lead to signiﬁcant amelioration in hyperglycemia-induced dyslipidemia and nonalcoholic
fatty liver disease.
1.Introduction
The polyol pathway is a glucose metabolic shunt that is
deﬁned by two enzymatic reactions catalyzed by aldose
reductase (AR, AKR1B1, EC1.1.1.21) and sorbitol dehydro-
genase (SDH, EC1.1.1.14), respectively [1, 2]. Biochemically,
AR catalyzes the rate-limiting reduction of glucose to
sorbitol, with the aid of cofactor NADPH. SDH converts
sorbitol to fructose using NAD+. AR/the polyol pathway
have been demonstrated to play important roles in the
development and progression of diabetic complications in
a number of tissues including kidney, retina, lens, and
peripheral neuron tissues [3–5]. In the liver, however, the
expression of AR is relatively low under normal physiological
conditions [6, 7]. By contrast, the hepatic expression of
sorbitol dehydrogenase, the second enzyme for the polyol
pathway, is quite high [8]. Due to the relatively lower levels
of expression of AR in the liver under normal situations,
relatively little attention had been paid to its roles in the
liver in the past. Recently, however, increasing evidence has
suggested that hepatic AR is dynamically regulated under a
variety of conditions. For instance, in rats fed with fructose,
hepatic AR is signiﬁcantly upregulated, which is associated
with impaired activation of Stat3 and suppressed activity
of PPARα in the liver [9]. In the Long Evans Cinnamon
rats, induction of hepatic AR expression was shown to be
associated with the development of hepatitis and hepatoma
[10]. Similarly, signiﬁcant upregulation of AR has also been
demonstrated in other diseased liver tissues from rodents to
humans [11–13].2 Experimental Diabetes Research
T h el i v e rt i s s u ep l a y sam a j o rr o l ei ne n e r g ym e t a b o l i s m ,
particularly glucose and lipid homeostasis. It is known that
diabetes, type II diabetes mellitus (T2DM) in particular, is
often associated with hepatic accumulation of triglycerides
in both rodents and humans, which might eventually lead
to the development of hepatic steatosis or nonalcoholic fatty
liver disease (NAFLD) [14–16]. Recently, we demonstrated
thatdeﬁciencyorinhibitionofARcausedsigniﬁcantdephos-
phorylation of hepatic PPARα, leading to the activation of
this transcriptional factor as well signiﬁcant reduction in
serum TG levels in streptozotocin-(STZ-) diabetic mice, an
experimental model for type I diabetes mellitus (T1DM)
[17]. Because T2DM is clinically much predominant than
T1DM, in this current study, we wanted to determine
whether AR also aﬀects PPARα in the liver of T2DM
db/db mouse models. Furthermore, we wanted to determine
how changes in AR activity might aﬀect the hepatic lipid
accumulation in the db/db mice. Our data suggest that
inhibition of AR in the T2DM db/db mice led to signiﬁcant
activation in hepatic PPARα and signiﬁcant reductions
in serum triglycerides (TG) and hepatic TG, suggesting
that under hyperglycemia, AR/the polyol pathway might
be greatly upregulated to contribute signiﬁcantly to the
hepatic regulation of TG metabolism and the development
ofnonalcoholicsteatohepatitis(NASH)ornonalcoholicfatty
liver disease (NAFLD).
2.MaterialsandMethods
2.1. Antibodies and Reagents. Antibodies were obtained from
the following vendors, respectively: ERK1/2 and phospho-
ERK1/2 (#9100), Cell Signaling (Beverly, Mass); PPARα
(sc9000) and AR (sc17735), Santa Cruz Biotechnology Inc.
(Santa Cruz, Calif); phosphoserine-12 PPARα (ab3484) and
phosphoserine-21 PPARα (ab3485), Abcam (Cambridge,
UK); β-actin (A1978), Sigma (St. Louis, Mo). Oil-red O and
other reagents were of analytical grade quality and from
Sigma (St. Louis, Mo). Zopolrestat (zopol) was synthesized
by the Department of Medicine Chemistry, Pﬁzer Global
Research and Development (Groton, Conn).
2.2. Lentivirus shRNA Construct. Recombinant lentiviral
vector expressing small hairpin RNA (shRNA) against
mouse AR (pLV-shAR) and its control (pLV-shNC) were
constructed by inserting double-strand shRNA oligonu-
cleotides into plasmid pLentiLox3.7 (pLL3.7) at the HapI
and XhoI sites. Control and shRNA oligonucleotides against
mouse AR were designed according to Ambion guide-
lines, with the sequences being 5 -ctggtcacacaacagaga-3 
and 5 -tacctaactcaggagaag-3 , respectively. Preparations of
lentiviruses were performed by cotransfecting the lentiviral
constructs with the packaging vectors into 293T cells using
Lipofectamine 2000 (Invitrogen). Virus-containing super-
natants were collected 48h after infection. Viruses were
recovered by ultracentrifugation at 110,000×gf o r1 . 5ha n d
resuspended in PBS. Titers were determined by infecting
293T cells with serial dilutions of concentrated lentiviral
preparations.
2.3. Animal Experiments. The animal experiments were
conducted according to protocols and guidelines approved
by the Xiamen University Institutional Animal Care and
Use Committee. The db/m (BKS.Cg-m/Leprdb/J) mice were
obtained from the Jackson Laboratory (Bar Harbor, Maine)
and bred to obtain six-week-old male db/db mice and their
lean control db/m mice for this study. All animals were
maintained on standard laboratory chow under a 12:12h
light-dark schedule. For AR inhibition by zopolrestat (zopol)
treatment, six-week-old db/db mice were randomly divided
into four experimental groups, namely, db/m mice, db/m
mice + zopol, db/db mice, and db/db mice + zopol. For
zopoltreatments,themicewereadministratedwith50mg/kg
body weight/day of zopol as a single daily intraperitoneal
injection for 28 days. The same volumes of saline were
also administrated to other control groups of mice. For in
vivo AR knock-down experiments, six-week-old db/db mice
wererandomlygrouped(4mice/group).In vivo transduction
of lentiviruses was achieved through tail vein injections of
0.1mL of concentrated viral suspension with a viral titer
of 1.0 × 109 IFU/mL in PBS. Twenty-eight days after zopol
treatment or lentiviral injection, mice were sacriﬁced and
tissues were dissected and immediately frozen in liquid N2
a n ds t o r e da t−80◦C until use.
2.4. Semiquantitative Analyses of mRNA Expression by RT-
PCR. Total RNA was isolated from tissues using Trizol
Reagent (Invitrogen) according to the manufacturer’s pro-
tocol. RT-PCR was performed to determine the levels of
acetyl CoA oxidase (Aco), carnitine palmitoyl transferase-
1( Cpt1), apolipoprotein C-III (ApoC3), and apolipopro-
tein A-V (ApoA5) mRNAs as previously described [17].
The primers used were 5 -CCGCCACCTTCAATCCAG-
AGTTA-3  and 5 -TCACAGTTGGGCTGTTGAGAATG-
3  (Aco), 5 -GGACGAATCGGAACAGGGATA-3  and 5 -
CCTTGTAATGTGCGAGCTGCA-3  (Cpt1), 5 -CCTCTT-
GGCTCTCCTGGCATCT-3  and 5 -TGCTCCAGTAGC-
CTTTCAGGG-3  (ApoC3), 5 -GTGGGAGAAGACAC--
CAAG-GCTC-3  and 5 -GGTCAATGGCCTGAGTAAA-
TGC-3  (ApoA5), 5 -CGAGACCCCACTAA-CATCAAA-
3  and 5 -AGTCTTCTGGGTGGCA-GTGAT-3  (GAPDH).
DNA ampliﬁcation was carried out using a High-Fidelity
PrimeScript RT-PCR Kit (TaKaRa). The PCR products
were electrophoresed on 2% agarose gels and visualized
by staining with ethidium bromide. The integrated density
values of the bands representing ampliﬁed products were
acquired and analyzed by Image-Pro Plus software (Media
Cybernetics, USA).
2.5. Western Blot Analyses. T i s s u e sw e r eh o m o g e n i z e dw i t h
Polytron in ice-cold buﬀer (1% Triton X-100, 50mM
HEPES pH 7.5, 150mMNaCl, 1mMEDTA, 10% glycer-
ine, 10mMNa4P2O7, 20mMglycerophosphate, 10mMNaF,
10mMsodiumorthovanadate,andproteinaseinhibitormix-
ture). The protein concentrations of the extracts were mea-
sured using a bicinchoninic acid protein assay kit (Pierce).
40μg protein of each sample was loaded and separated
on a 12% SDS-polyacrylamide gel and transferred to
polyvinylidene diﬂuoride (PVDF) membranes (Millipore).Experimental Diabetes Research 3
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Figure 1: Eﬀect of zopol treatment or AR knock-down on serum TG levels (a) and TC levels (b) of db/db mice. Lean control mouse groups
are db/m, n = 6 and db/m + zopol, n = 4; diabetic mouse groups are db/db, n = 6; db/db + zopol, n = 6 and db/db + pLV-shNC (n = 4);
db/db + pLV-shAR (n = 4). Values are expressed as the mean ± SEM. ∗P<0.05; NS: not signiﬁcant.
Blotted membranes were then incubated either anti-ERK
or anti-phospho-ERK (1:1000) or anti-PPARα (1:500) or
anti-phospho-PPARα (1:1000) or anti-AR (1:500) in TBS-
0.1% Tween-20 with 5% nonfat milk at 4◦C overnight.
After several washes, the membranes were incubated with
horseradish peroxidase-conjugated anti-rabbit IgG or anti-
goat IgG (1:2000) in TBS-0.1% Tween-20 with 5% nonfat
milk. The detection was achieved using the supersignal
chemiluminescent substrate kit (Pierce).
2.6. Blood Sample Analyses. Serum TG levels were measured
using a colorimetric assay (Sigma, TR0100). Total serum
cholesterol was measured using a cholesterol reagent kit
(Jiancheng Biotech, Nanjing, China).
2.7. Liver TG Analyses. Liver TG was extracted by chloro-
form/methanol. Brieﬂy, pulverized liver was homogenized in
PBS, then extracted with chloroform/methanol (2:1), dried
overnight, and resuspended in a solution of 60% butanol
40%TritonX-114/methanol(2:1).LivertotalTGlevelswere
measured using a colorimetric assay (Sigma, TR0100).
2.8. Oil-Red O Staining. Frozen liver sections of 10μm
thickness were ﬁxed in 4% paraformaldehyde and stained
with 0.5% oil-red O using standard procedures.
2.9.StatisticalAnalyses. Alldatawereprocessedandanalyzed
by GraphPad software (Prism 5.0) and expressed as mean ±
SEM. Students’ t-test was used for pair-wise comparisons
and one-way ANOVA with Bonferroni’s Multiple Compari-
son Test for multigroup analyses. Probability values less than
0.05 (∗) were considered to be statistically signiﬁcant; those
less than 0.01 (∗∗)m o r es o .
3. Results
3.1. AR Inhibition-Reduced Serum TG but Not Serum TC
Levels in Diabetic db/db Mice. To determine the eﬀects of
AR on systemic lipid metabolism, we measured the serum
TG and TC levels in db/db mice after zopol treatment
or AR knockdown (Figure 1). As shown in Figure 1(a),
zopol treatment for 4 weeks caused a signiﬁcant reduction
in the serum TG levels in the 10-week-old male db/db
mice (110.6 ± 14.17mg/dL for db/db + zopol versus
149.3 ± 5.06mg/dL for db/db, P<0.05) but had little
eﬀects on the control db/m mice. A similar reduction in
serum TG level was also observed in 10-week-old db/db
mice transduced with lentiviruses carrying shRNA for AR
(107.6 ± 12.38mg/dL for db/db + pLV-shAR versus 141.6 ±
11.51mg/dL for db/db + pLV-shNC, P>0.05), although
the diﬀerence was not signiﬁcant statistically. In contrast
to serum TG, no signiﬁcant change in serum TC levels
was observed in both db/db mice treated with zopol or
db/db mice transduced with lentiviruses carrying AR shRNA
(Figure 1(b)), which is consistent with our previous ﬁndings
in the STZ-induced T1DM mouse model [17]. Together
theseresultsindicatethatinhibitionofARleadstosigniﬁcant
reductions in serum TG but not serum TC.
3.2. AR Inhibition-Reduced Hepatic TG in Diabetic db/db
Mice. To determine how changes in AR expression and
activity might aﬀect hepatic lipid accumulation, we analyzed
the TG contents in the liver tissues of 10-week-old male
db/db mice after zopol treatment for 28 days or lentivirus-
mediated AR knockdown. Oil-red O staining of liver tissues
showedthatsubstantialfatdropletswerediﬀuselydistributed
in the hepatic lobules from the 10-week-old untreated
db/db mice. In the liver of the db/db mice received zopol
for 28 days, however, much little and smaller fat droplets
were observed (Figure 2(a)). Similar reductions in hepatic
lipid accumulation were observed in db/db mice treated
with lentiviruses containing AR-shRNA expression cassette.
The results from tissue staining were further conﬁrmed by
biochemical analyses of hepatic TG content (Figure 2(b)).
Zopol treatment in db/db mice signiﬁcantly reduced hepatic4 Experimental Diabetes Research
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Figure 2: Eﬀect of zopol treatment or AR knockdown on hepatic lipid in db/db mice. (a) Oil-red O staining of liver tissues of db/db mice
after zopol treatment. (A) db/m; (B) db/m + zopol; (C) db/db; (D) db/db + zopol; (E) db/db + pLV-shNC; (F) db/db + pLV-shAR. Results
are typical for 3mice/group. Original magniﬁcation, ×100. (b) AR inhibition or AR knock-down reduced liver TG of db/db mice as analyzed
chemically.Leancontrolmousegroupsaredb/m(n = 6)anddb/m+zopol(n = 4);diabeticmousegroupsaredb/db(n = 6);db/db+zopol
(n = 6) and db/db + pLV-shNC (n = 4); db/db + pLV-shAR (n = 4). Values are expressed as the mean ± SEM. ∗P<0.05; ∗∗∗P<0.001.
TG by about 60% (12.89 ± 1.47mg/g tissue for db/db +
zopol versus 23.06 ± 1.66mg/g tissue for db/db, P<0.001).
Similarly, AR knockdown in db/db mice also signiﬁcantly
reduced hepatic TG by about 40% (14.99 ± 2.11mg/g tissue
for db/db + pLV-shAR versus 24.69 ± 3.02mg/g tissue for
db/db + pLV-shNC, P<0.05).
3.3. AR Inhibition Led to Signiﬁcant Dephosphorylation of
Hepatic ERK1/2 and PPARα in the db/db Mice. In STZ-
induced T1DM mice, we demonstrated previously that AR
deﬁciency or AR inhibition led to signiﬁcant dephospho-
rylation of hepatic ERK1/2 and PPARα [17]. To determine
whether this is also the case in the T2DM db/db mice,
we examined the hepatic expression and phosphorylation
of these proteins in 10-week-old db/db mice and its
control db/m mice. As shown in Figure 3(a), with the
elevation in hepatic AR expression in the db/db mice, the
phosphorylation of both ERK1/2 and PPARα (at Serine-
12 and Serine-21) in the db/db mice was signiﬁcantly
enhanced. In db/db mice received zopol treatment for 28
days, however, the phosphorylation of both ERK1/2 and
PPARα was greatly attenuated. Noteworthy is that a slight
increase in phosphoserine-21 PPARα level was also observed
for db/m mice following the zopol treatment. However,
statistical analyses indicated the increase in pPPARα (S21) in
db/m mice with zopol is not signiﬁcant (data not shown).
Similar attenuations in phosphorylation of both ERK1/2 and
PPARα were also observed for db/db mice transduced with
lentiviruses carrying shRNA for AR (Figure 3(b)). Together
these results suggest that, consistent with the results from
the STZ-induced T1DM mice, in vivo inhibition of AR in
T2DM db/db mice also lead to dephosphorylation of both
ERK1/2 and PPARα, which might eventually lead to the
activation of hepatic PPARα to signiﬁcantly aﬀect hepatic
lipid metabolism.
3.4. Dephosphorylation of PPARα Is Associated with Altered
Expression of Hepatic Aco and ApoA5. To determine the
eﬀects of PPARα dephosphorylation on its target genes,
we analyzed the expression of hepatic Aco, ApoA5, ApoC3,
and Cpt-1 mRNAs by semiquantitative RT-PCR for liver
tissues from the control mice and db/db mice receivedExperimental Diabetes Research 5
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Figure 3: Eﬀects of AR on PPARα and ERK1/2 phosphorylation in db/db mice. (a) Representative Western blot for four independent
experiments. Liver tissues were dissected and analyzed 28 days after zopol treatment. (b) Representative Western blot for four independent
experiments. Liver tissues were dissected and analyzed 28 days after transduction with lentiviruses containing pLV-shAR or pLV-shNC.
pERK1/2, phospho-ERK1/2; pPPARα (S12), phosphoserine-12 PPARα;p P P A R α (S21), phosphoserine-21 PPARα.
zopol treatment or db/db mice transduced with lentiviruses
carryingARshRNA.AsshowninFigure4(a),comparedwith
untreated db/db mice, mRNA expression of Aco and ApoA5
in zopol-treated db/db mice elevated by approximately 93%
(P<0.05) and 73% (P<0.05), respectively. Meanwhile,
zopol-treated db/db mice had a slight but not signiﬁcant
lower hepatic expression of ApoC3 mRNA expression and a
slight but not signiﬁcant higher expression of Cpt-1 mRNA
expression than the untreated db/db mice. The upregulation
of hepatic Aco mRNA after zopol treatment was further
conﬁrmed in db/db mice transduced with lentiviruses car-
rying AR shRNA (Figure 4(b)). Probably due to incomplete
knockdown, however, no signiﬁcant changes were observed
for hepatic mRNA expression of ApoA5, ApoC3,a n dCpt-
1. Together these data indicate that inhibition of AR caused
activationofhepaticPPARαtoaltertheexpressionandactiv-
ity of major hepatic enzymes involved in lipid homeostasis
in the T2DM db/db mice, which might have signiﬁcant
impact on hepatic lipid accumulation and the development
or progression of NASH and NAFLD.
4. Discussion
AR/the polyol pathway is widely recognized to be involved in
the pathogenesis of diabetic complications such as cataracts,
nephropathy, and neuropathy [4, 18]. In contrast, relatively
little attention has been paid to their potential roles in
the development of diabetic lipid disorders. In spite of
this, several studies have shown the possible link between
activation/deactivation of AR/the polyol pathway and altered
regulation in lipid metabolism. It has been reported that
in diabetic patients with dyslipidemia, there are signiﬁcant
increases in plasma or serum and urinary sorbitol and
fructose, indicating that the increased ﬂux in the polyol
pathway is concomitant with diabetic dyslipidemia [19, 20].
Moreover, pharmacological administration of several AR
inhibitors including zopol were shown to reduce blood TG
in rats [21], tumor bearing mice [22], and diabetic human
patients [23], respectively. More recently, our group reported
that in STZ-induced T1DM mouse models, genetic AR
deﬁciency or in vivo inhibition by chemical inhibitors of AR
signiﬁcantly improved hyperglycemia-induced dyslipidemia
[17]. It is therefore of interest to determine whether AR reg-
ulates PPARα and aﬀects hepatic lipid metabolism in T2DM
models. In line with our expectation, we demonstrated in
this current study that inhibition of AR by zopol treatment
or transduction with lentiviruses carrying shRNA for AR
greatly reduced hyperglycemia-induced lipid accumulation
and hepatic steatosis in T2DM db/db mice. Furthermore, we
showed that AR probably regulates hepatic lipid metabolism
in part by modulating the status of PPARα phosphorylation
to alter its activity.
In our current study, we utilized both chemical inhibitor
and mRNA knockdown as means for the inhibition of AR.
The inclusion of AR knockdown as an alternative approach
for the inhibition of AR was necessary because we wanted
to exclude the possible side or toxic eﬀects and nonspeciﬁc
inhibition that might be associated with chemical inhibitors
of AR. Although both chemical inhibition and AR knock-
down resulted in similar eﬀects on hepatic lipid metabolism
and mRNA expression levels of PPARα and its target
genes, AR knockdown appeared to be slightly less eﬀective
than zopol treatment. This is probably due to incomplete
knockdown of AR as only a single injection was performed
and that was maintained for 4 weeks before the analyses.
The exact mechanisms underlying suppression of lipid
accumulation or hepatic steatosis by inhibition of AR are
not completely clear at this moment and require further6 Experimental Diabetes Research
0
1
2
3
4
5
db/m
db/m + zopol
db/db
d b / d b+z o p o l
∗
∗
NS
NS
Aco ApoA5 ApoC3 Cpt1
m
R
N
A
e
x
p
r
e
s
s
i
o
n
(
G
A
P
D
H
c
a
l
i
b
r
a
t
e
d
)
(a)
m
R
N
A
e
x
p
r
e
s
s
i
o
n
(
G
A
P
D
H
c
a
l
i
b
r
a
t
e
d
)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
db/db + pLV-shNC
db/db + pLV-shAR
∗
NS
NS NS
Aco ApoA5 ApoC3 Cpt1
(b)
Figure 4: Hepatic mRNA expression of Aco, ApoA5, ApoC3, and Cpt-1 as analyzed by semiquantitative RT-PCR in db/db mice. (a) Liver
tissues were dissected and analyzed 28 days after zopol treatment. (b) Liver tissues were dissected and analyzed 28 days after transduction
with lentiviruses containing pLV-shAR or pLV-shNC. Values are expressed as the mean ± SEM (n = 3-4). ∗P<0.05; NS: not signiﬁcant.
investigations.Atthismoment,however,themechanismsfor
increased lipid degradation and mechanisms for decreased
lipid synthesis both appear to be functional. Our demon-
stration that inhibition of AR led to the activation of
PPARα through its dephosphorylation contributes in part to
increased hepatic lipid degradation following inhibition of
AR. It is well established that PPARα is a central regulator
for hepatic glucose and lipid metabolism as well as the
development of lipid disorders including hepatic steatosis
and NAFLD [24–29]. Once activated, it will tend to promote
lipid catabolism by upregulating the expression of lipid
catabolic enzymes such as lipoprotein lipase and ApoA5
[30] and downregulating ApoC3 [31]. Consistent with this,
two important lipid catabolic enzymes Aco and ApoA5
were signiﬁcantly upregulated as a consequence of PPARα
activation, although not much change in mRNA expression
was observed for Cpt1 and ApoC3. Inhibition of AR, on
the other hand, might also result in reduced lipid synthesis.
Under hyperglycemic conditions, for example, abundant
glucosemightbechanneledintothehyperglycemia-activated
AR/the polyol pathway to generate a substantial amount
of fructose in the liver. Fructose has long been known
to be highly lipogenic and can contribute signiﬁcantly to
hepatic lipogenesis, adipogenesis, insulin resistance, obesity,
hypertension, metabolic syndrome, hepatic steatosis, and
NAFLD [9, 32–47] in both human and rodents. When
AR is inhibited or when the polyol pathway is blocked, it
can therefore be expected that endogenous hepatic fructose
generationwillbegreatlyreducedsuchthatfructose-induced
lipogenesis in the liver will also be suppressed, thereby
leading to the suppression of hepatic steatosis or NAFLD.
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